Esmorap 40 mg 14 capsules

Esmorap 40 mg 14 capsules

Compound:
Each sachet contains:
Esomeprazole 40 mg.
Auxiliary components:
Copolymer of methacrylic acid and ethyl acrylate, talc, sucrose, spherical granules, hyprolose, hypromellose, triethyl citrate, magnesium stearate, glycerol monostearate, polysorbate 80, dextrose, crospovidone, xanthan gum, anhydrous citric acid, iron oxide yellow dye.
Properties:
Antiulcer agent - proton pump inhibitor, dextrorotatory isomer of omeprazole; reduces the secretion of hydrochloric acid in the stomach by specific inhibition of the proton pump in parietal cells.
Being a weak base and turning into an active form in the acidic environment of the secretory tubules of the parietal cells of the gastric mucosa, it activates and inhibits the proton pump - H + / K + ATPase.
Suppresses basal and stimulated secretion of hydrochloric acid.
Indications:
Gastroesophageal reflux disease (GERD): erosive reflux esophagitis (treatment), prevention of relapse in patients with cured esophagitis, symptomatic treatment of GERD.
As part of combination therapy: peptic ulcer of the stomach and duodenum associated with Helicobacter pylori (treatment and prevention).
Dosage and administration:
1 capsule daily with or without food.
The duration of the course is determined by the doctor.
Contraindications:
Hypersensitivity (including to substituted benzimidazoles), simultaneous administration with atazanavir (atazanavir plasma concentration decreases), lactation period.
With caution.
Pregnancy.
Precautionary measures:
In the presence of any alarming symptoms (for example, such as significant spontaneous weight loss, frequent vomiting, dysphagia, vomiting of blood or melena), as well as in the presence of a stomach ulcer (or if a stomach ulcer is suspected), the possibility of malignancy should be excluded, since treatment with esomeprazole can lead to a smoothing of symptoms, and thus. delay correct diagnosis.
Patients taking the drug for a long period (especially more than 1 year) should be under regular medical supervision.
During treatment with proton pump inhibitors, plasma concentrations of gastrin increase as a result of reduced intragastric secretion of HCl.
In patients taking proton pump inhibitors for a long time, the formation of glandular cysts in the stomach is more common.
These phenomena are due to physiological changes as a result of inhibition of HCl secretion.
The cysts are benign and tend to disappear.
Side effects:
Frequent (0.1-1%): headache, abdominal pain, diarrhea, flatulence, nausea, vomiting, constipation.
Rare (0.01-0.1%): dermatitis, itching, urticaria, dizziness, dry mouth.
Storage method:
At a temperature not higher than 30 degrees.
In a dry place.
Package:
The carton contains 28 sachets of 2.5 mg.